Scholarlink

<p>The treatment of breast cancer (BC) faces multiple challenges, including high recurrence rates, drug resistance, and toxic side effects. This study constructed a cell membrane-mimicking biomimetic cascade nanoreactor, mCGH@ZIF, which is loaded with the photosensitizer chlorin e6 (Ce6), glucose oxidase (GOx), and hemin, enabling synergistic starvation-photodynamic therapy. Within the tumor microenvironment, GOx depleted glucose and generated H₂O₂; hemin converted H₂O₂ into O₂ in situ, effectively alleviated hypoxia and amplified the generation of Ce6-mediated singlet oxygen; and the cancer cell membrane coating enabled both immune evasion and homologous targeting. In vitro experiments demonstrated that mCGH@ZIF significantly suppressed 4T1 breast cancer cell proliferation while preserving excellent biocompatibility. This strategy established a closed-loop system integrating glucose depletion, oxygen production, and reactive oxygen species (ROS) generation, overcame the limitations of monotherapies, and offered a novel approach for precision combination therapy in breast cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A zeolite imidazolate (ZIF-8)-based system for synergistic photodynamic/starvation therapy of breast cancer

  • 期刊论文

  • 发表日期：

    2025年11月12日

查看全文
  • Fenglan Li,
  • Yuanyuan Zhang,
  • Chenliu Ye,
  • Junyang Zhuang

摘要

The treatment of breast cancer (BC) faces multiple challenges, including high recurrence rates, drug resistance, and toxic side effects. This study constructed a cell membrane-mimicking biomimetic cascade nanoreactor, mCGH@ZIF, which is loaded with the photosensitizer chlorin e6 (Ce6), glucose oxidase (GOx), and hemin, enabling synergistic starvation-photodynamic therapy. Within the tumor microenvironment, GOx depleted glucose and generated H₂O₂; hemin converted H₂O₂ into O₂ in situ, effectively alleviated hypoxia and amplified the generation of Ce6-mediated singlet oxygen; and the cancer cell membrane coating enabled both immune evasion and homologous targeting. In vitro experiments demonstrated that mCGH@ZIF significantly suppressed 4T1 breast cancer cell proliferation while preserving excellent biocompatibility. This strategy established a closed-loop system integrating glucose depletion, oxygen production, and reactive oxygen species (ROS) generation, overcame the limitations of monotherapies, and offered a novel approach for precision combination therapy in breast cancer.